Scientists at Gladstone Institutes discovered that phosphorylation of the huntingtin protein prevents loss of critical brain cells and protected against behavioral symptoms in a mouse model of Huntington's disease. The study suggests a potential therapeutic target for treating the devastating neurodegenerative disorder.
Researchers at the Gladstone Institutes have developed a new method to consistently activate mesenchymal stromal cells to produce anti-inflammatory proteins, enhancing their immune-suppressing effects. This breakthrough could lead to improved treatments for inflammatory bowel disease and organ transplant rejection.
Scientists from Gladstone Institutes identified salicylic acid's cancer-fighting properties by inhibiting epigenetic regulators p300 and CBP. Salicylic acid suppresses inflammation and cell growth, offering new clinical possibilities for drugs like aspirin and diflunisal.
Research at Gladstone Institutes found that the apoE4 protein disrupts brain activity in mice, impairing memory replay and consolidation. The study suggests that disrupted slow gamma activity during ripples is a major consequence of apoE4 expression, likely leading to impaired memory loss.
Researchers at Gladstone Institutes successfully reprogrammed human skin cells into beating heart cells and neural stem cells using chemical cocktails. This breakthrough could lead to new treatments for heart failure and neurodegenerative diseases.
Researchers at Gladstone Institutes develop a new method to create three-dimensional human heart tissue from stem cells, addressing limitations of existing techniques. This breakthrough enables scientists to study heart cells in their proper context, enhancing the discovery of treatments for heart disease.
Scientists at the Gladstone Institutes have invented a new way to read and interpret the human genome, using machine learning technology to predict gene-enhancer interactions. The TargetFinder tool accurately predicts complex three-dimensional interactions up to 85% of the time, opening the door to treating genetic diseases.
Researchers at Gladstone Institutes found that increasing levels of protein tau may reverse cognitive deficits caused by Alzheimer's disease. They discovered that tau disrupts memory in models of Alzheimer's disease by depleting protein KIBRA, which is critical for memory formation.
Scientists have developed a modified form of CRISPR that can silence genes in stem cells more efficiently and precisely than the original CRISPR-Cas9 system. This new technology allows for flexible gene suppression and reversal, enabling versatile investigations into genetic diseases.
Scientists at Gladstone Institutes discover a new type of cell that can organically develop into heart cells and replicate. The induced expandable cardiovascular progenitor cells (ieCPCs) significantly improved heart function in mice after a heart attack, offering a promising potential treatment for heart failure.
Researchers at Gladstone Institutes found that three transcription factors -- NKX2-5, TBX5, and GATA4 -- must interact for proper heart development. Without these interactions, severe congenital heart defects occur. The study revealed the proteins' genomic and physical interactions, providing new insights into treating heart disease.
Researchers at Gladstone Institutes uncover a neural circuit that controls walking and find a new target for treating Parkinson's disease. Dopamine depletion disrupts movement by miscommunicating between the basal ganglia and thalamus, leading to an imbalance between go and stop pathways.
A new study developed a comparable test of learning and memory for humans as the one used in mice, addressing limitations in translating results from animals to humans. The virtual version of the Morris water maze was found to show significant impairments in both Alzheimer's disease model mice and early-stage AD patients.
Scientists at Gladstone Institutes discovered a novel regulator of body weight: the P75 neurotrophin receptor. Lowering levels of p75 NTR protected mice from developing obesity, diabetes, and fatty liver disease on a high-fat diet. The receptor plays a key role in regulating metabolic processes that control body weight.
Researchers at the Gladstone Institutes have successfully converted human skin cells into fully-functional insulin-producing pancreatic cells. These new cells protected mice from developing diabetes in a mouse model of the disease, offering a promising approach to personalized cell therapy for patients with diabetes.
Researchers found that BRCA1 depletion impairs brain cell function and contributes to cognitive decline in Alzheimer's disease. The study suggests that therapeutic manipulation of BRCA1 may prevent neuronal damage and cognitive decline in patients with Alzheimer's disease or at risk for the disease.
Researchers identified a gene, KLF15, which activates to enhance muscle endurance and alleviate muscular dystrophy without the negative side effects of glucocorticoids. Boosting KLF15 in skeletal muscle improved exercise capacity and strength in DMD patients, suggesting new treatment possibilities.
Blood T cells are resistant to HIV's primary death pathway, but not lymphoid tissue T cells. The researchers suggest that studying lymphoid tissue T cells could lead to a better understanding of the virus and potentially new treatments.
A study from the Gladstone Institutes reveals that a single drop of blood in the brain can trigger an autoimmune response akin to multiple sclerosis. Fibrinogen, a blood-clotting factor, activates microglia and recruits peripheral immune cells, causing myelin damage and inflammation.
Researchers at Gladstone Institutes mapped the discovery path to two FDA-approved drugs, revealing that a large network of scientists contributed over decades. The study proposes new metrics to quantify the influence of individual scientists in accelerating future cures.
Researchers repurposed salsalate to reverse tau-related dysfunction in an animal model of frontotemporal dementia, effectively lowering tau levels and rescuing memory impairments.
Researchers found that impairments in mitochondria can deplete cellular energy levels and cause neuronal dysfunction in a model of neurodegenerative disease. The study revealed the energy threshold needed to support synaptic vesicle cycling, highlighting the importance of mitochondrial function in brain cells.
Researchers found that HIV's cell-to-cell transmission is the primary mechanism for massive CD4 T cell death, leading to the progression from HIV to AIDS. Disrupting this transmission effectively stopped cell death.
A randomized trial of daily oral HIV pre-exposure prophylaxis (PrEP) in men and transgender women who have sex with men found no link between Truvada use and depression. Half of participants reported clinically significant depression, highlighting the need for further research on PrEP's impact during vulnerable times.
Researchers identified a cellular mechanism that can be targeted to treat ALS by increasing levels of protein hUPF1, which successfully protected against cell death in both genetic and sporadic versions of the disease. Treating this pathway may also have implications for frontotemporal dementia.
A team of researchers has developed a novel method to regenerate bone tissue using the protein signals produced by stem cells. The approach is more sustainable and less risky than current standard therapies, which rely on ground-up bones from cadavers.
Researchers at Gladstone Institutes discovered a way to prevent MS onset in mice by blocking SIRT1, suggesting its role in autoimmune disorders. The treatment also shows promise for other diseases like type I diabetes.
Researchers at Gladstone Institutes have discovered a chain of events that cause healthy valves to become bone-like. They identified three key genes that are altered in calcific aortic valve disease (CAVD) and found a potential therapeutic target by manipulating their activity, pointing to novel treatments for the condition.
Researchers from Gladstone Institutes challenge conventional theory on HIV latency, proposing it's an evolutionarily advantageous survival tactic. The study reveals the virus controls its own on/off switch through protein Tat, enabling it to evade eradication by antiretroviral therapies.
Researchers found no significant relationship between BMI and gut microbiome types, instead highlighting genetic variation in bacterial strains. Dr. Pollard's team developed a computational shortcut to improve accuracy of microbiome studies.
A study found that increasing klotho levels can protect against learning and memory deficits in a mouse model of Alzheimer's disease, counteracting the effects of Alzheimer-related toxins. Klotho's benefits may be due to its effect on neurotransmitter receptors involved in learning and memory.
Scientists at Gladstone Institutes have discovered a way to enhance CRISPR's precision while boosting its efficiency using small molecules. This breakthrough has important implications for correcting disease-causing genetic mutations and creating personalized therapeutics.
Researchers at Gladstone Institutes discovered a new memory regulator in astrocytes, which improved memory in healthy mice and prevented impairments in Alzheimer's disease models. The study suggests that targeting A2A adenosine receptors may offer a potential treatment for improving memory.
Two deadly viruses, hepatitis C and Kaposi's sarcoma-associated herpesvirus, were found to target common host proteins that are critical for human biology. By studying protein interactions between viruses and cells, scientists have identified potential new targets for anti-viral treatments.
Researchers found that nicotinamide riboside (NR) prevents noise-induced hearing loss by increasing the activity of protein sirtuin 3, which is critical for mitochondrial function. NR also showed promise in preventing long-term and short-term hearing loss, regardless of when it was administered.
A new study reveals that microbicides targeting HIV are less effective when exposed to semen due to its amyloid fibrils, which enhance the virus's infectiousness. Researchers suggest creating a compound targeting both the virus and these protein aggregates to improve drug efficacy.
Researchers at Gladstone Institutes found that progranulin deficiency can increase amyloid-beta plaque formation, neuroinflammation, and cognitive dysfunction in a mouse model of Alzheimer's disease. Increasing progranulin levels via gene therapy effectively prevented these abnormalities and protected against cell death.
Researchers found retinal thinning as an early marker for frontotemporal dementia, prior to cognitive symptoms. The retina acts as a 'window to the brain,' and studying it can track changes in neurons.
Researchers found that reducing brain levels of tau protein effectively blocks disease development in a mouse model of Dravet syndrome. This approach also improved cognitive and behavioral abnormalities associated with the syndrome.
Scientists transplanted inhibitory neuron progenitors into two mouse models of Alzheimer's disease, improving learning and memory abilities. The treatment replenished brain cells lost due to apoE4, regulating brain activity.
A team of scientists at the Gladstone Institutes has identified a new way to make latent HIV reveal itself by increasing its gene expression noise. This approach, known as the 'shock and kill' method, holds great promise for treating latent HIV infection.
Researchers at Gladstone Institutes and UCSF have made a breakthrough in regenerative medicine by transforming skin cells into mature, fully functioning liver cells. The new method offers hope for treating liver failure and could serve as an alternative to liver transplants.
Researchers at the Gladstone Institutes have devised a method to reprogram skin cells into cells that closely resemble beating heart cells, exhibiting twitching and contracting patterns. The addition of one genetic factor, Oct4, accelerated the transformation, revealing promising results for pharmaceutical-based therapies.
Researchers have found a way to efficiently edit the human genome one letter at a time, boosting ability to model human disease and paving the way for therapies that fix genetic 'bugs'. The new technique highlights out-of-the-box thinking critical for scientific success.
Researchers at Gladstone Institutes develop technique to replenish destroyed ß-cells in animal models, showing promise for a permanent solution to manage type 1 diabetes. The study uses regenerative medicine to transform skin cells into insulin-producing pancreas cells.
Researchers at the Gladstone Institutes found that mutant LRRK2 accumulation leads to cell death in Parkinson's neurons, and that alpha-synuclein plays a crucial role in this process. By understanding the interplay between these two proteins, scientists may develop new therapeutic strategies to target the disease's underlying mechanisms.
Researchers at Gladstone Institutes have identified the precise chain of molecular events driving CD4 T cell death in HIV-infected individuals, leading to AIDS. They also discovered an existing anti-inflammatory drug that blocks this process, paving the way for a Phase 2 clinical trial.
A new study confirms that regular Truvada use can reduce one's risk for contracting HIV without leading to increased sexual risk behavior. The research provides further proof of the effectiveness of Truvada as an HIV prevention strategy.
Robert Mahley and his team will use the funding to identify new chemical compounds that can target apolipoprotein E4 (apoE4), the strongest genetic risk factor for developing Alzheimer's. They aim to develop small-molecule therapies that prevent apoE4's damaging effects on the brain.
A team at Gladstone Institutes has developed a molecular sensor that can detect the earliest signs of multiple sclerosis, including heightened thrombin activity in the brain. This breakthrough could lead to early diagnosis and treatment options, shedding light on the underlying molecular processes that drive the disease.